Published: 3 February 2016
Author(s): Dario Maratea, Francesca Venturini
Section: Letters to the Editor

A major challenge for regulatory agencies is balancing the need for rapid access to drugs for new indications against the limited information on their benefit–risk ratio. The processes described by Martinalbo and colleagues depicted a European scenario with different national frameworks [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.